PAVmed Inc. (NASDAQ:PAVM) Short Interest Down 65.0% in August

PAVmed Inc. (NASDAQ:PAVM) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 7,939 shares, a decline of 65.0% from the August 15th total of 22,659 shares. Based on an average daily trading volume, of 13,726 shares, the short-interest ratio is presently 0.6 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Investors Weigh In On PAVmed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PAVM. Jane Street Group LLC raised its holdings in PAVmed by 392.9% in the second quarter. Jane Street Group LLC now owns 52,676 shares of the company’s stock worth $32,000 after purchasing an additional 41,990 shares in the last quarter. Geode Capital Management LLC grew its position in PAVmed by 74.8% in the 4th quarter. Geode Capital Management LLC now owns 168,832 shares of the company’s stock worth $40,000 after purchasing an additional 72,258 shares during the period. BlackRock Inc. purchased a new stake in PAVmed during the 2nd quarter valued at $102,000. Finally, Two Seas Capital LP bought a new position in shares of PAVmed during the 2nd quarter valued at $2,742,000. 19.93% of the stock is owned by hedge funds and other institutional investors.

PAVmed Stock Down 2.1%

PAVM stock opened at $4.18 on Friday. PAVmed has a fifty-two week low of $3.85 and a fifty-two week high of $28.44. The company has a market capitalization of $33.44 million, a price-to-earnings ratio of -0.26 and a beta of 0.53. The business’s 50 day moving average price is $5.12 and its two-hundred day moving average price is $6.91. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.19 and a current ratio of 1.19.

Analyst Ratings Changes

PAVM has been the subject of a number of research analyst reports. Ascendiant Capital Markets dropped their price target on PAVmed from $65.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Weiss Ratings downgraded shares of PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $56.00.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.